Skip to main content

Bangalore scientists develop new TB drug regimen with better outcomes, lower toxicity

Tuberculosis causes 250,000 deaths in India each year

Researchers at the Indian Institute of Science (IIS) have discovered a new drug combination that promises better outcome in treating Tuberculosis (TB), which causes 250,000 deaths in India each year.

Animal studies on mice shows that the drug Pranlukast (PRK) not only killed tuberculosis bacteriumbut also compromised its survival strategies within the cells, said the research, published in the February issue of online journal, EMBO Molecular Medicine.

"The problem with TB is the bacterium keeps developing resistance against new drugs and at least 15 drugs have been abandoned so far, either due to resistance against the drug or severe toxicity," says Dr Avdhesha Suroli, lead researcher of the project.

"Our research has proved this combination could work better and be an effective addition to the TB drug pipeline that needs to be reinvented frequently. We need the government or pharma companies to come forward and conduct Phase II trials to know the efficacy and dosage escalation," said Dr Suroli, who led the six-member team that has been working on the project for the past five years.

The researchers propose a combination of Pranlukast with the standard-of-care therapy drugs, to be highly efficient against Tb pathogen, thereby providing an opportunity to use this novel drug combination for TB therapeutics.

"Three drugs are currently being used — Isoniazid, Rifampin and Ethambutol -- in combination therapy and we recommend Ethambutol be replaced with PRK as it could work better," says Dr Suroli.

PRK has the potential to be included directly into the therapeutic regime against Tb as it has approval for treatment of asthma in the US, Japan and Europe.

Although the past decade has seen major developments in the TB drug discovery pipeline, there is a constant need for improved therapeutic interventions.


Popular posts from this blog

Isotretinoin in India: A tragedy in the offing

Isotretinoin in India: A tragedy in the offing
Wednesday, March 28, 2007 08:00 IST 
Seema Thakral

Isotretinoin is the drug of choice for severe calcitrant cystic acne vulgaris, which often causes scarring and depression from disfigurement. Isotretinoin has been called "the greatest medical advance of the 1980's." A majority of patients with acne are permanently cleared after a four to five months course of treatment. It has also been used off-label for a variety of oncology uses including: cervical cancer, head and neck cancer, squamous cell cancer of the skin, juvenile chronic myelogenous leukemia (CML), and neuroblastoma. However, the drug is a proved teratogen and carries a significant risk of birth defects, if it taken during pregnancy. Birth defects, which have been documented following isotretinoin exposure include abnormalities of the face, eyes, ears, skull, central nervous system, cardiovascular system, and thymus and parathyroid glands. There is an increased risk …

The Influence of TheTourniquet on blood draw

[1] Various methods are used to obtain specimens for hematocritdetermination in neonates. We evaluated arterial sampling andfound this method to be acceptable. Arterial values correlatedclosely with simultaneously obtained venous samples. Venousblood obtained with a tourniquet had a significantly higherhematocrit than that obtained without a tourniquet.[2] Influence of tourniquet application on venous blood sampling for serum chemistry, hematological parameters, leukocyte activation and erythrocyte mechanical propertiesBackground: Venous blood sampling is usually performed using a tourniquet to help locate and define peripheral veins to achieve successful and safe venipuncture. Despite widespread usage of tourniquets for venipuncture by medical and laboratory staff, very few are aware of the effects of tourniquet application on laboratory parameters. In addition, definitive guidelines regarding when and how to use a tourniquet for blood sampling are lacking. The aim of the present stu…

Happy 2010!